Literature DB >> 2285677

The effects of testosterone propionate and methenolone enanthate on the healing of humeral osteotomies in the Wistar rat.

M Frankle1, J Borrelli.   

Abstract

A randomized blind prospective study was carried out to determine if an anabolic androgenic steroid with a high anabolic/androgenic ratio, Group A, (1/0.05) methenolone enanthate (me), compared to an anabolic/androgenic agent with a low anabolic/androgenic ratio, Group B, (1.0/1.0) testosterone propionate (tp), compared to a control, Group C, cottonseed oil (co), affected midhumeral osteotomy healing in 100 two-month-old female Wistar rats. The rats received 4 mg/kg me, 4 mg/kg te, and equal volumes of co weekly. The rats were sacrificed at 2, 4, and 6 weeks. The entire humerus with the healing osteotomy was carefully dissected until all soft tissue attachments were stripped. The healing callus was then subjected to (1) biochemical analysis (hexosamine, hydroxyproline, and calcium), (2) biomechanical testing (progressive distraction of the callus at 1 mm/min on an electrohydraulic materials test system, model 1331, Instron Corp, Canton, MA, and (3) histology. Results of the biochemical testing demonstrated that the percentage of calcium in the healing callus at 2 weeks in group B (tp) was 7.3 +/- 1.0, and this value was greater than that in group C (co), 4.8 +/- 1.6 (p greater than .01), and greater than that in group A (me), 5.6 +/- 0.6 (p greater than .01). At 4 weeks, the percentage of calcium in the callus in group B (tp) was 6.8 +/- 1.9, in group A (me) 7.3 +/- 3.7, and these values were both greater than that in group C (co), 3.9 +/- 2.2 (p greater than .02 and .01, respectively). At 6 weeks the percentage of calcium in the callus in group B (tp) was 11.7 +/- 3.9 and in group A (me) 12.7 +/- 3.9, and again these values were both greater than that in group C (co), 6.7 +/- 2.6 (p greater than .02 and .01, respectively). The remainder of the biochemical analysis, hexosamine and hydroxyproline content, did not show a statistical difference in groups A, B, and C at 2, 4, and 6 weeks. The biomechanical studies and histology also failed to show statistical differences between the three groups at 2, 4, and 6 weeks. The conclusion of this study is that an agent with a low androgenic activity does not increase calcium callus concentrations early in the course of fracture healing compared to an agent with higher androgenic activity. As healing progresses, both agents increase the concentration of calcium in osteotomy healing. The clinical significance of this study is that agents with low androgenic activities favorably influence osteotomy healing and may be clinically useful because they lack unwanted virilizing activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285677     DOI: 10.3109/08941939009140340

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  4 in total

1.  Influence of anabolic steroid on tibial fracture healing in rabbits - a study on experimental model.

Authors:  Farida Ahmad; Syed Mobashir Yunus; Adil Asghar; N A Faruqi
Journal:  J Clin Diagn Res       Date:  2013-01-01

Review 2.  Anabolic Androgenic Steroids in Orthopaedic Surgery: Current Concepts and Clinical Applications.

Authors:  Alexander E Weber; Matthew C Gallo; Ioanna K Bolia; Emmett J Cleary; Todd E Schroeder; George F Rick Hatch
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-01-04

3.  Evaluating the affect and reversibility of opioid-induced androgen deficiency in an orthopaedic animal fracture model.

Authors:  Jesse Chrastil; Christopher Sampson; Kevin B Jones; Thomas F Higgins
Journal:  Clin Orthop Relat Res       Date:  2014-02-19       Impact factor: 4.176

4.  Whole bone testing in small animals: systematic characterization of the mechanical properties of different rodent bones available for rat fracture models.

Authors:  Peter M Prodinger; Peter Foehr; Dominik Bürklein; Oliver Bissinger; Hakan Pilge; Kilian Kreutzer; Rüdiger von Eisenhart-Rothe; Thomas Tischer
Journal:  Eur J Med Res       Date:  2018-02-14       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.